[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20064325L - Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes - Google Patents

Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes

Info

Publication number
NO20064325L
NO20064325L NO20064325A NO20064325A NO20064325L NO 20064325 L NO20064325 L NO 20064325L NO 20064325 A NO20064325 A NO 20064325A NO 20064325 A NO20064325 A NO 20064325A NO 20064325 L NO20064325 L NO 20064325L
Authority
NO
Norway
Prior art keywords
diabetes
heteroberlaminopyrazole
treatment
derivatives useful
derivatives
Prior art date
Application number
NO20064325A
Other languages
English (en)
Inventor
Philip L Wickens
Libing Chen
Steven R Magnuson
Joachim Rudolph
Chih-Yuan Chuang
Alan Olague
Ning Ql
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of NO20064325L publication Critical patent/NO20064325L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelse vedrører heteroarylaminopyrazolforbindelser, farmasøytiske sammensetninger og fremgangsmåter for å behandle diabetes og relaterte forstyrrelser.
NO20064325A 2004-02-27 2006-09-25 Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes NO20064325L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54833104P 2004-02-27 2004-02-27
US57290604P 2004-05-20 2004-05-20
PCT/US2005/005794 WO2005086656A2 (en) 2004-02-27 2005-02-24 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes

Publications (1)

Publication Number Publication Date
NO20064325L true NO20064325L (no) 2006-11-22

Family

ID=34976070

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064325A NO20064325L (no) 2004-02-27 2006-09-25 Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes

Country Status (17)

Country Link
US (2) US7517878B2 (no)
EP (1) EP1720863A4 (no)
JP (1) JP2007525513A (no)
KR (1) KR20060124727A (no)
AR (1) AR049418A1 (no)
AU (1) AU2005220723A1 (no)
BR (1) BRPI0508051A (no)
CA (1) CA2557527A1 (no)
EC (1) ECSP066883A (no)
IL (1) IL177232A0 (no)
MA (1) MA28479B1 (no)
NO (1) NO20064325L (no)
PE (1) PE20051159A1 (no)
RU (1) RU2006134004A (no)
TW (1) TW200538130A (no)
UY (1) UY28774A1 (no)
WO (1) WO2005086656A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007122485A (ru) 2004-11-17 2008-12-27 Мийкана Терапьютикс Ингибиторы киназы
WO2006065590A2 (en) * 2004-12-16 2006-06-22 Xtl Biopharmaceuticals Inc. Pyridine and pyrimidine antiviral compositions
EP1866298A2 (en) 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
ES2535854T3 (es) * 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
PL2013204T3 (pl) 2006-03-24 2015-09-30 Array Biopharma Inc Analogi 2-aminopirydyny jako aktywatory glukokinazy
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
EP2173745A2 (en) * 2007-03-23 2010-04-14 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
AU2008262291A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
PT2209778E (pt) 2007-09-21 2012-12-06 Array Biopharma Inc Derivados de piridin-2-il-amino-1,2,4-tiadiazole como activadores de glucoquinase para o tratamento de diabetes mellitus
US9315449B2 (en) * 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
EP2135865A1 (de) 2008-06-17 2009-12-23 Bayer CropScience AG Substituierte 1-(Diazinyl) pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
EP2194052A1 (de) 2008-12-06 2010-06-09 Bayer CropScience AG Substituierte 1-(Thiazolyl)- und 1-(Isothiazolyl)pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
IL302896A (en) * 2009-10-06 2023-07-01 Millennium Pharm Inc Heterocyclic compounds used as PDK1 inhibitors
WO2011073098A1 (de) 2009-12-15 2011-06-23 Bayer Cropscience Ag 1-(heteroaryl)-pyrazol-4-yl-essigsäuren, verfahren zu deren herstellung und deren verwendung als herbizide und pflanzenwachstumsregulatoren
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
US20170291890A1 (en) * 2014-09-17 2017-10-12 Epizyme, Inc. Heterocycle substituted amino-pyridine compounds and methods of use thereof
WO2016092559A1 (en) * 2014-12-12 2016-06-16 Oat & Iil India Laboratories Private Limited Substituted pyrazole derivatives having activity as fungicides
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
KR101725292B1 (ko) * 2016-03-30 2017-04-10 한국과학기술연구원 항암 활성을 갖는 신규 피리미딘-4-카르복시산 유도체
PE20190395A1 (es) 2016-06-16 2019-03-13 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405207A1 (de) * 1994-02-18 1995-08-24 Bayer Ag N-Pyrazolylaniline und N-Pyrazolylaminopyridine
US20020103185A1 (en) * 2000-08-31 2002-08-01 Sanner Mark A. Pyrazole derivatives
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7319102B1 (en) * 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors

Also Published As

Publication number Publication date
JP2007525513A (ja) 2007-09-06
RU2006134004A (ru) 2008-04-10
US20050192294A1 (en) 2005-09-01
PE20051159A1 (es) 2006-02-22
CA2557527A1 (en) 2005-09-22
WO2005086656A2 (en) 2005-09-22
KR20060124727A (ko) 2006-12-05
EP1720863A4 (en) 2009-04-22
AU2005220723A1 (en) 2005-09-22
US7517878B2 (en) 2009-04-14
TW200538130A (en) 2005-12-01
IL177232A0 (en) 2006-12-10
ECSP066883A (es) 2006-11-24
UY28774A1 (es) 2005-08-31
EP1720863A2 (en) 2006-11-15
US20090209451A1 (en) 2009-08-20
AR049418A1 (es) 2006-08-02
WO2005086656A3 (en) 2005-12-29
MA28479B1 (fr) 2007-03-01
BRPI0508051A (pt) 2007-07-17

Similar Documents

Publication Publication Date Title
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
DE602005017895D1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
NO20081421L (no) Midler for hindring og behandling av forstyrrelser som involverer modulering av RYR-reseptorer
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
EA200870569A1 (ru) Соединения и способы модуляции fxr
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
SE0403006D0 (sv) New compounds
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
NO20082096L (no) Azaindol-2-karboksamidderivativer
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
ATE466841T1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application